SEC Form 4 · accession 0001209191-18-021497
Clearside Biomedical, Inc. · CLSD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clay Thorp
Director · 10% Owner
Period of report
Mar 21, 2018
Accepted (ET)
Mar 23, 2018 · 5:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001539029
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3,F4 | Mar 21, 2018 | S | 100,000 | $12.27 | D | 3,666,394 | I | See Footnotes |
| Common StockF5,F6,F3,F4 | Mar 22, 2018 | S | 33,630 | $12.07 | D | 3,632,764 | I | See Footnotes |
| Common StockF7,F8,F3,F4 | Mar 23, 2018 | S | 5,231 | $12.02 | D | 3,627,533 | I | See Footnotes |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Consists of (i) 2,940 shares sold by Hatteras NC Fund, LP ("Hatteras NC"), (ii) 38,350 shares sold by Hatteras Venture Partners III, LP ("HVP III"), (iii) 3,480 shares sold by Hatteras Venture Affiliates III, LP ("HVA III"), (iv) 6,200 shares sold by Hatteras Venture Partners IV, LP ("HVP IV") and (v) 49,030 shares sold by Hatteras Venture Partners IV SBIC, LP ("HVP IV SBIC").
- F2This transaction was executed in multiple trades at prices ranging from $12.00 to $12.49, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- F3The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of HVP IV and Hatteras NC. HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC.
- F4The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
- F5Consists of (i) 989 shares sold by Hatteras NC, (ii) 12,897 shares sold by HVP III, (iii) 1,170 shares sold by HVA III, (iv) 2,085 shares sold by HVP IV and (v) 16,489 shares sold by HVP IV SBIC.
- F6This transaction was executed in multiple trades at prices ranging from $12.00 to $12.21, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- F7Consists of (i) 154 shares sold by Hatteras NC, (ii) 2,006 shares sold by HVP III, (iii) 182 shares sold by HVA III, (iv) 324 shares sold by HVP IV and (v) 2,565 shares sold by HVP IV SBIC.
- F8This transaction was executed in multiple trades at prices ranging from $12.00 to $12.10, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.